CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ReGen Biologics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ReGen Biologics Inc
411 Hackensack Ave Fl 10
Phone: (201) 651-5140p:201 651-5140 HACKENSACK, NJ  07601-6326  United States Ticker: RGBOQRGBOQ

This company ceased filing statements with the SEC on 6/16/2011.

Business Summary
ReGen Biologics, Inc. (ReGen) is a development stage orthopedic products company that develops, manufactures and markets tissue growth and repair products for United States and global markets. The Company's collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. Some of these applications are marketable while others are in various stages of development. ReGen’s first approved product using its collagen matrix technology is the Menaflex collagen meniscus implant device (also known as the CMI), which is marketed for sale in the European Union (EU), Switzerland, Turkey, and the Republic of South Africa, through the Company’s subsidiary, ReGen Biologics AG.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/200912/31/2008YesYesYes--

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer Gerald E.Bisbee 79 1/1/2012 12/19/1989
Chief Financial Officer, Chief Administrative Officer Dennis W.O'Dowd 1/1/2012 1/1/2012
Senior Vice President - Sales and Marketing JeffreyChandler 53 12/1/2008 12/1/2008
6 additional Officers and Directors records available in full report.

Business Names
Business Name
RBio, Inc.
ReGen Biologics AG
ReGen Biologics, Inc.
RGBOQ

General Information
Number of Employees: 16 (As of 12/31/2008)
Outstanding Shares: 9,778,940 (As of 8/3/2009)
Shareholders: 234
Stock Exchange: OTC
Federal Tax Id: 232476415
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023